16.52
price up icon3.40%   0.525
 
loading
Schlusskurs vom Vortag:
$16.00
Offen:
$15.95
24-Stunden-Volumen:
239.54K
Relative Volume:
0.14
Marktkapitalisierung:
$2.86B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-382.71M
KGV:
-6.3073
EPS:
-2.62
Netto-Cashflow:
$-325.64M
1W Leistung:
+3.40%
1M Leistung:
+11.41%
6M Leistung:
-33.21%
1J Leistung:
-39.86%
1-Tages-Spanne:
Value
$15.86
$16.65
1-Wochen-Bereich:
Value
$15.50
$16.65
52-Wochen-Spanne:
Value
$12.72
$34.47

Immunovant Inc Stock (IMVT) Company Profile

Name
Firmenname
Immunovant Inc
Name
Telefon
917-580-3099
Name
Adresse
320 WEST 37TH STREET, NEW YORK, NY
Name
Mitarbeiter
362
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IMVT's Discussions on Twitter

Vergleichen Sie IMVT mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMVT
Immunovant Inc
16.50 2.86B 0 -382.71M -325.64M -2.62
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.44 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.43 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.08 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
555.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.75 28.51B 3.81B -644.79M -669.77M -6.24

Immunovant Inc Stock (IMVT) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-03 Eingeleitet Jefferies Hold
2025-01-03 Herabstufung Wolfe Research Outperform → Peer Perform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-10-09 Bestätigt Oppenheimer Outperform
2024-03-28 Eingeleitet Oppenheimer Outperform
2024-03-13 Eingeleitet Goldman Buy
2024-02-20 Eingeleitet JP Morgan Overweight
2024-02-15 Eingeleitet Wolfe Research Outperform
2023-12-12 Eingeleitet Deutsche Bank Buy
2023-10-13 Hochstufung UBS Neutral → Buy
2023-09-26 Hochstufung Raymond James Mkt Perform → Outperform
2023-05-01 Eingeleitet BofA Securities Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-31 Eingeleitet Piper Sandler Overweight
2023-03-30 Eingeleitet Stifel Buy
2023-02-15 Eingeleitet Cantor Fitzgerald Overweight
2023-02-13 Hochstufung Guggenheim Neutral → Buy
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-09-26 Herabstufung UBS Buy → Neutral
2021-12-08 Eingeleitet Wells Fargo Equal Weight
2021-08-03 Herabstufung Robert W. Baird Outperform → Neutral
2021-08-02 Herabstufung Credit Suisse Neutral → Underperform
2021-06-01 Herabstufung Guggenheim Buy → Neutral
2021-06-01 Herabstufung Stifel Buy → Hold
2020-10-28 Eingeleitet UBS Buy
2020-10-12 Eingeleitet Guggenheim Buy
2020-10-08 Eingeleitet Stifel Buy
2020-10-02 Eingeleitet Credit Suisse Outperform
2020-08-26 Bestätigt H.C. Wainwright Buy
2020-08-25 Eingeleitet Raymond James Outperform
2020-07-29 Eingeleitet H.C. Wainwright Buy
2020-02-24 Eingeleitet SVB Leerink Outperform
Alle ansehen

Immunovant Inc Aktie (IMVT) Neueste Nachrichten

pulisher
Jun 17, 2025

GAMMA Investing LLC Buys 5,229 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Jun 17, 2025
pulisher
Jun 15, 2025

Learn to Evaluate (IMVT) using the Charts - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 15, 2025

Immunovant, Inc. (NASDAQ:IMVT) Receives $38.33 Consensus Target Price from Brokerages - Defense World

Jun 15, 2025
pulisher
Jun 13, 2025

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Forecasts Immunovant FY2027 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 08, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Wellington Management Group LLP - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Two Sigma Advisers LP Buys New Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Ameriprise Financial Inc. Makes New Investment in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Jun 07, 2025
pulisher
Jun 04, 2025

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Dexcom (DXCM) and Immunovant (IMVT) - The Globe and Mail

Jun 04, 2025
pulisher
Jun 03, 2025

Immunovant (IMVT) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Jun 03, 2025
pulisher
Jun 02, 2025

Long Term Trading Analysis for (IMVT) - news.stocktradersdaily.com

Jun 02, 2025
pulisher
Jun 02, 2025

Leerink Partnrs Estimates Immunovant FY2030 Earnings - Defense World

Jun 02, 2025
pulisher
May 31, 2025

IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus - MSN

May 31, 2025
pulisher
May 30, 2025

Immunovant price target lowered to $35 from $51 at H.C. Wainwright - TipRanks

May 30, 2025
pulisher
May 30, 2025

Immunovant’s Promising Future: Buy Rating Backed by Strategic Advancements and Strong Cash Position - TipRanks

May 30, 2025
pulisher
May 30, 2025

Immunovant Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 30, 2025
pulisher
May 30, 2025

H.C. Wainwright Adjusts Price Target for Immunovant (IMVT) Amid Future Prospects | IMVT Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Immunovant Insiders Sell US$5.9m Of Stock, Possibly Signalling Caution - simplywall.st

May 30, 2025
pulisher
May 30, 2025

Immunovant (NASDAQ:IMVT) Shares Gap Up After Better-Than-Expected Earnings - Defense World

May 30, 2025
pulisher
May 30, 2025

Immunovant, Inc. Reports Strategic Progress and Financial Results - TipRanks

May 30, 2025
pulisher
May 29, 2025

IMVT INVESTIGATION ALERT: Investigation Launched into Private Placement Transaction by Immunovant, Inc. and Attorneys Encourage Investors to Contact Law Firm - The Malaysian Reserve

May 29, 2025
pulisher
May 29, 2025

Immunovant, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence By Stocktwits - Investing.com India

May 29, 2025
pulisher
May 29, 2025

Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence - MSN

May 29, 2025
pulisher
May 29, 2025

Immunovant, Inc. SEC 10-K Report - TradingView

May 29, 2025
pulisher
May 29, 2025

Immunovant (IMVT) Secures Strong Financial Position with $714 Million in Cash | IMVT Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Immunovant's Fiscal Q4 Net Loss Widens - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Earnings Flash (IMVT) IMMUNOVANT INC. Reports Q4 Loss $0.64 Per Share, vs. FactSet Est of $-0.71 - marketscreener.com

May 29, 2025
pulisher
May 29, 2025

Immunovant's Clinical Trials Show 74% Success in Myasthenia Gravis, Advancing 6 Disease Programs - Stock Titan

May 29, 2025
pulisher
May 28, 2025

Immunovant (IMVT) to Release Earnings on Wednesday - Defense World

May 28, 2025
pulisher
May 25, 2025

Bank of America Corp DE Buys 114,511 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

May 25, 2025
pulisher
May 23, 2025

(IMVT) Trading Advice - news.stocktradersdaily.com

May 23, 2025
pulisher
May 21, 2025

IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm - Business Wire

May 21, 2025
pulisher
May 21, 2025

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33 - Defense World

May 21, 2025
pulisher
May 16, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by Northern Trust Corp - Defense World

May 16, 2025
pulisher
May 15, 2025

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings? - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

The Manufacturers Life Insurance Company Has $889,000 Stock Position in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

May 15, 2025
pulisher
May 14, 2025

Transcript : Immunovant, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 04 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Smart Money Ratings For 20 Most Undervalued Stocks - Insider Monkey

May 14, 2025
pulisher
May 12, 2025

Immunovant Inc (NASDAQ: IMVT) Is The Among Hot Stock Right Now - Stocksregister

May 12, 2025
pulisher
May 11, 2025

Dimensional Fund Advisors LP Sells 58,463 Shares of Immunovant, Inc. (NASDAQ:IMVT) - Defense World

May 11, 2025
pulisher
May 09, 2025

Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back? - Insider Monkey

May 09, 2025
pulisher
May 09, 2025

Raymond James Financial Inc. Buys Shares of 20,382 Immunovant, Inc. (NASDAQ:IMVT) - Defense World

May 09, 2025
pulisher
May 08, 2025

11 Stocks That Will Bounce Back According to Analysts - Insider Monkey

May 08, 2025
pulisher
May 06, 2025

Investor’s Delight: Immunovant Inc (IMVT) Closes Weak at 15.22, Down -3.67 - DWinneX

May 06, 2025
pulisher
May 02, 2025

Ins & Outs: Biopharma players shuffle c-suite ranks - BioProcess International

May 02, 2025
pulisher
May 02, 2025

(IMVT) Investment Analysis - news.stocktradersdaily.com

May 02, 2025
pulisher
May 02, 2025

Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Wells Fargo & Company MN - Defense World

May 02, 2025
pulisher
May 01, 2025

A company insider recently sold 1,925 shares of Immunovant Inc [IMVT]. Should You Sale? - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

IMVT’s Stock Market Adventure: -34.80% YTD Growth Amidst Volatility - investchronicle.com

May 01, 2025
pulisher
May 01, 2025

Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com

May 01, 2025

Finanzdaten der Immunovant Inc-Aktie (IMVT)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.95
price up icon 1.40%
$36.00
price down icon 0.06%
$21.32
price down icon 0.15%
$99.07
price down icon 1.72%
$108.80
price up icon 2.21%
biotechnology ONC
$244.86
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):